Transcriptomics (RNA) Technology
Living cells function through a set of genes called genome. The genetic information contained within the genome is utilized by the cell through a DNA copying mechanism referred to as RNA transcription. RNA transcripts are subsequently translated into proteins which, until recently, were thought to perform virtually all cellular functions. Scientific research conducted during the past few years has unexpectedly shown that the functions of RNA molecules go beyond a passive role in the expression of protein-coding genes. It has been estimated that at least half of the human genome is transcribed and as much as 98% of the transcripts made are non-protein-coding RNA. The new scientific field dedicated to studying the entire set of RNA transcripts of an organism has been accorded the term "Transcriptomics". This new field of research holds a great promise for delivering the next generation of human therapeutics and is the current focus of a number of highly valued, young biotechnology companies. Our Transcriptomics technology relates to methodology for rapid identification of all RNAs that can be made from any given piece of DNA (See Figure, Part A). With this unique capability we are able to compare RNA profiles generated from Normal Tissue against Cancer Tissue and quickly identify new cancer targets for therapeutic intervention (See Figure, Part B). The Company owns the exclusive patents to this process. The Company has already identified one, very promising anti-cancer RNAi drug candidate (Adva-R46) and is searching for more. Our Adva-R46 has proven very effective in killing cancer cells in vitro and is anticipated to enter animal testing later this year.
